Ty21a, the Vi capsular polysaccharide vaccine, and Vi-rEPA are effective in reducing<unk>  fever with low rates of adverse effects. Newer vaccines such as Vi-TT (PedaTyph) are awaiting field trials to demonstrate efficacy against natural exposure. The oral Ty21a vaccine prevents around one-half of<unk>  cases in the first three years after vaccination. The injectable Vi polysaccharide vaccine prevented about two-thirds of<unk>  cases in the first year and had a cumulative efficacy of 55% by the third year. The efficacy of these vaccines has only been demonstrated in children older than two years. Vi-rEPA vaccine, a new conjugate form of the injectable Vi vaccine, may be more effective and prevents the disease in many children under the age of five years. In a trial in 2-to-5-year-old children in Vietnam, the vaccine had more than 90 percent efficacy in the first year and protection lasted at least four years. Schedule Depending on the formulation it can be given starting at the age of two (ViPS), six (Ty21a), or six months (TCV).
Typhoid vaccine
Typhus vaccine
Anthrax vaccines
Measles vaccine
Polio vaccine
Tetanus vaccine
Pertussis vaccine
Rabies vaccine